This past week was rough for most investors, but it was a lot harder for a handful of cascading stocks. There were nearly a dozen U.S. exchange-listed companies with market caps north of $1 billion that tumbled by at least 20% last week.
Marvell Technology(NASDAQ: MRVL), VF Corp.(NYSE: VFC), and Hims & Hers Health(NYSE: HIMS) are three of those names, sliding 23%, 23%, and 20%, respectively, this past week. They are well positioned to bounce back. Let’s go over what tripped up three of the market’s biggest decliners. Then let’s turn to how they can bounce back.
A “beat and raise” performance during earnings season isn’t always going to resonate when the overall market is heading lower. Case in point: On Wednesday, semiconductor stock Marvell posted poorly received results for its fiscal fourth quarter of 2025. Revenue for the quarter rose a slightly better-than-expected 27% to hit $1.82 billion.
Marvell’s performance was boosted by a 78% surge in data center revenue that now makes up 75% of the top-line mix. But that means the balance of its business isn’t doing so well. Revenue for the next three largest segments declined 35% to 38% from where Marvell landed a year earlier.
That’s not a deal-breaker, but considering all but a quarter of Marvell’s business is thriving on the AI-fueled surge in demand for its data center solutions, that’s undeniably the driving force for the stock these days.
Image source: Getty Images.
Marvell also came through on the bottom line. A small profit reversed a prior-year loss, but on an adjusted basis, net income climbed 30% to reach $0.60 a share. Wall Street pros were modeling a profit of $0.59 a share. Marvell came through with modest single-digit percentage quarterly beats through all of fiscal 2025.
The near term looks more promising than last week’s stock chart. Marvell’s guidance calls for revenue growth to accelerate to 62% in the current quarter, and adjusted earnings should more than double.
One Wall Street firm downgraded the stock following the report, and several more slashed their price targets. They’re generally encouraged by the Marvell’s ability to keep growing its AI business through custom ASIC programs as well as optical networking, but they’re taking a cautious approach given the current market environment. The stock seems compelling at 25 times forward earnings, with a multiple just below 20 if you look out to the following fiscal year.
It’s not enough to be an iconic brand to thrive these days, but VF has no shortage of apparel and footwear platforms in its arsenal. This is the parent company of Vans, The North Face, and Timberland. Unfortunately, VF’s shoelaces and jacket zippers have come undone. Revenue is declining the for the third consecutive year that will wrap up at the end of this month, but year-over-year top-line gains did turn marginally positive in its latest quarter.
VF is attempting a strategic reset, but an investor day presentation on Thursday failed to assure the market.
The company’s goals are ambitious. It sees a clear path to double its apparel and equipment segments, while also tripling its footwear revenue. VF also has strong goals for the other end of the income statement. The company believes it can deliver $500 million to $600 million in operating income expansion through cost cuts in sales, general, and administrative expenses and through gross margin expansion.
Wells Fargo lowered its price target on the shares. It argues that VF’s presentation was light on near-term financial updates and cautious in sizing up the prospects for a turnaround at Vans. The good news is that VF is trading for a reasonable 18 times analyst profit targets for the new fiscal year that starts in three weeks. It has managed three straight quarters of double-digit percentage beats on the bottom line. There’s also a 1.9% dividend to keep patient investors close.
The higher they rise, the harder they fall. Hims & Hers Health was one of last year’s hottest stocks, soaring 183% as folks took to its telehealth platform. It had doubled again in 2025 by mid-February, but that run didn’t last. The company has come under fire lately, with the days likely to be numbered for its most effective weight-loss platform.
Novo Nordisk‘s (NYSE: NVO) Wegovy and Eli Lilly‘s (NYSE: LLY) Zepbound are popular with patients tackling obesity. These GLP-1 weekly injectables were doing well until demand outstripped supply. Production shortages opened up an FDA loophole through which third parties, including Hims & Hers Health, could create compounded versions of patented treatments during a shortfall of product. Now that Novo Nordisk has cleared its production obstacles, a big part of the business here could be up in the air soon.
The bullish case for Hims & Hers Health is that with the stock cut in half from last month’s all-time high, it’s easier to make a valuation case. Although the future of its GLP-1 compounding shots is in doubt, consumers now trust the platform that provides online access to discreetly and conveniently obtain medical solutions. There is still a healthy path to keep growing its revenue at a double-digit percentage clip. The doctor is in, but the doctor also never really went away.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia:if you invested $1,000 when we doubled down in 2009,you’d have $292,207!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,326!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $480,568!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
Wells Fargo is an advertising partner of Motley Fool Money. Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool recommends Marvell Technology and Novo Nordisk. The Motley Fool has a disclosure policy.
